NITTO BOSEKI CO.,LTD. (3110) Stock Price

Nitto Boseki operates six business segments as follows.

1. **Electronic Materials Business**: Nitto Boseki develops, manufactures, and sells fiberglass products for electronic material applications. Related companies such as Nitto Glassfiber Industrial and Baotek Industrial Materials Ltd. supply raw materials and products to Nitto Boseki.

2. **Medical Business**: The company develops, manufactures, and sells in vitro diagnostic pharmaceuticals. Nitto Boseki Medical operates in this field, while Nittobo America Inc. handles the manufacturing and sales of antisera.

3. **Composite Materials Business**: The company provides fiberglass products for plastic reinforcement applications. Fuji Fiberglass supplies products to Nitto Boseki.

4. **Materials and Chemical Business**: The company develops, manufactures, and sells fiberglass products for industrial materials, chemical products, interlining materials, functional materials, and cleaning cloths. Nitto Boseki Advantex operates in this field.

5. **Thermal Insulation Business**: The company provides glasswool products for thermal insulation, heat retention, and sound absorption applications. Paramount Glass Industrial handles manufacturing and sales, and purchases some raw materials from Nitto Boseki.

6. **Other Business**: The company engages in the design, manufacturing, sales, installation, maintenance, and service of industrial machinery and equipment. Nitto Boseki Techno undertakes equipment construction projects, while Soyō sells fiberglass products.

Nitto Boseki is advancing a medium-term management plan (fiscal years 2024-2027) based on its long-term vision "Big VISION 2030," aiming to realize a sustainable society. The plan targets growth as a global niche leader in three priority areas: "Environment and Energy," "Digital Society," and "Health, Safety, and Security."

In its electronic materials business, the company is expanding production capacity for specialty glass to meet demand from AI servers. In its medical business, it is advancing high-functionality development of in vitro diagnostic pharmaceuticals and expanding market presence domestically and internationally. Strategic capital investment and strengthened research and development capabilities in these fields form the pillars of its growth strategy.

Additionally, the company is pursuing deeper exploration of existing businesses and new business opportunities in composites, materials and chemicals, and thermal insulation materials. Particularly, it is exploring new business opportunities in fiberglass and fiber sectors, with initiatives aimed at sustainable growth beyond 2030.

As environmental targets, the company has set goals to reduce CO2 emissions by 30% compared to fiscal year 2013 levels by fiscal year 2030, and to achieve carbon neutrality by fiscal year 2050. To this end, it has established a Sustainability Promotion Committee to examine and implement specific measures.